Breaking News
June 22, 2018 - Administering nitric oxide gas after heart surgery may decrease risk of kidney problems
June 22, 2018 - Measuring levels of ethyl sulphate in hair can help assess alcohol consumption
June 22, 2018 - Researchers develop robot bloodhound that can rapidly detect odors on the ground
June 22, 2018 - AAA doses first patients in two clinical studies with PSMA-R2 for prostate cancer
June 22, 2018 - Pelvic pain a major issue for women nearing mid-life, research reveals
June 22, 2018 - Researchers develop reliable DNA barcodes for biomedical research
June 22, 2018 - New risk-prediction model may help identify diabetic patients at high risk of pancreatic cancer
June 22, 2018 - Study reveals how mTORC1-driven changes in crowding could influence major diseases
June 22, 2018 - Researchers uncover new therapeutic opportunity in the treatment of malignant melanoma
June 22, 2018 - UC Riverside researcher receives grants to advance cancer, ALS research
June 22, 2018 - Radiation therapy alone may be enough to treat older, sicker patients with anal cancers
June 22, 2018 - Technical report describes how to make accurate particle size measurements on carbon black samples
June 22, 2018 - Nocdurna (desmopressin acetate) Approved by FDA as First Sublingual Tablet to Treat Nocturia due to Nocturnal Polyuria
June 22, 2018 - Neuroscientists locate neurons in the brain that respond when a visual target is found
June 22, 2018 - First human Keystone virus infection reported
June 22, 2018 - New study reveals how ‘good’ bacteria help in regulating our metabolism
June 22, 2018 - Osteopathic manual therapy affecting the diaphragm improves chronic low back pain
June 22, 2018 - Researchers create revolutionary model to study pulmonary diseases
June 22, 2018 - Diagnosing Heart Disease Using AI
June 22, 2018 - Increasing biodefense risks posed by synthetic biology
June 22, 2018 - Many Women Report Vasomotor Symptoms in Their 60s
June 22, 2018 - Rare mutation of gene carried by Quebec family gives insight into how the brain is wired
June 22, 2018 - Chemists find new way to make enzymes do a non-natural reaction
June 22, 2018 - Summer is good time to check for signs of skin cancer
June 22, 2018 - Innovative method can help identify patients with spastic cerebral palsy
June 22, 2018 - Exercise alters characteristics of blood to reduce inflammation in obese people
June 22, 2018 - Researchers examine complications across different types of breast reconstructive surgeries
June 22, 2018 - Rhesus macaque model could be useful to test therapies for congenital Zika virus syndrome
June 22, 2018 - AHA: New Insights Into Sickle Cell and Stroke Risk
June 22, 2018 - Doctors prescribe opioids at high rates to those at increased overdose risk
June 22, 2018 - Reduction in US cigarette smoking rates
June 22, 2018 - Preconception binge drinking may have negative effect on future offspring
June 22, 2018 - FDA expands approval of novel diabetes management device to include younger pediatric patients
June 22, 2018 - Researchers confirm weight loss benefits of the 16:8 diet
June 22, 2018 - FDA approves Eversense CGM system for use in adults with diabetes
June 22, 2018 - State opioid monitoring programs are not created equal
June 22, 2018 - Autistic teens who are bullied have higher rates of depression
June 22, 2018 - Penn Medicine team launches universal stroke awareness program
June 22, 2018 - Scientists discover the molecular trigger of necroptosis
June 22, 2018 - Researchers report unusually high levels of herpesvirus in the brains of people with Alzheimer’s disease
June 22, 2018 - Theoretical models predict how juveniles evolve to be more susceptible than adults to infection
June 22, 2018 - USC study reveals how the cell launches emergency response to repair damaged DNA
June 22, 2018 - $1.9 million grant aims to enhance behavioral health services in community-based settings
June 22, 2018 - New 3D imaging technique could improve arthritis treatment
June 22, 2018 - Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy
June 22, 2018 - Polarized cells give the heart its fully developed form
June 21, 2018 - Stem cells appear to help fight obesity in animal models
June 21, 2018 - Harnessing Pediatric Cancer Genomic Data in the Cloud
June 21, 2018 - Training nursing students with cost-effective 3D-printed task trainers
June 21, 2018 - Study provides insight into how planned and spontaneous movements are processed in the brain
June 21, 2018 - Suicide Prevention | SAMHSA – Substance Abuse and Mental Health Services Administration
June 21, 2018 - From designer microbes to stem cells, researchers are investigating new strategies to treat bowel disease
June 21, 2018 - Study suggests state-of-the-art genomic testing for routine autopsy of stillbirths
June 21, 2018 - Christiana Care Health System opens first Epilepsy Monitoring Unit in Delaware
June 21, 2018 - CDC: Obesity Prevalence Higher in Non-Metropolitan Counties
June 21, 2018 - Youths Treated for Non-Suicidal Self Harm at Increased Risk of Suicide Within a Year
June 21, 2018 - WVU researchers increase colorectal cancer screening rates in West Virginia
June 21, 2018 - Pediatric kidney recipients often have subclinical inflammation
June 21, 2018 - OHSU Knight Cancer Institute Director wins 2018 Tang Prize in Biopharmaceutical Science
June 21, 2018 - Researchers study broader effects of neonics on wildlife
June 21, 2018 - Study provides new insight on how antibiotics affect the gut microbiome
June 21, 2018 - InHealth Technologies becomes exclusive distributor of RENÚ Voice, RENÚ Gel in the United States
June 21, 2018 - New analysis links higher BMI to lower breast cancer risk for younger women
June 21, 2018 - Interactive preclinical PET-MR workshop demonstrates benefits of multi-modality imaging
June 21, 2018 - Gene signature could improve early diagnosis of TB
June 21, 2018 - Psychiatric Drug Lithium Tied to Birth Defect Risk
June 21, 2018 - Preclinical study suggests ARID1a may be useful biomarker for immunotherapy
June 21, 2018 - Risks of cancer and mortality found to be lowest in light drinkers
June 21, 2018 - Fetal immune cells are fast-acting first responders to microbes in adulthood
June 21, 2018 - Researchers invent medical device for proliferation, differentiation of neural stem cells
June 21, 2018 - Study explores current understanding of human physiology, pathology, trauma and surgery in space
June 21, 2018 - Scientists explore interactions between chromosomes 12 and 17
June 21, 2018 - People with severe obesity constantly try to reduce or control their weight
June 21, 2018 - Relaxing ‘brain tingles’ may have benefits for both mental and physical health
June 21, 2018 - Breakthrough discovery reveals brain metals that may drive progression of Alzheimer’s disease
June 21, 2018 - New methods of fragment-based lead discovery to identify potential antibiotics
June 21, 2018 - Recovery and Treatment | NIH MedlinePlus the Magazine
June 21, 2018 - Study finds cell-free DNA profiling as versatile method to monitor UTIs
June 21, 2018 - ‘Hidden’ driver discovered that helps prime the anti-tumor immune response
June 21, 2018 - Groundbreaking discovery could be key to preventing cancer metastasis
Gene Therapy Offers Hope for Inherited Retinal Disorder

Gene Therapy Offers Hope for Inherited Retinal Disorder

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  • Patients with inherited retinal disease due to biallelic mutation in the RPE65 gene had sustained functional vision improvement when treated with voretigene neparvovec (Luxturna), according to a phase III study in 29 patients.
  • Note that RPE65 is an isomerohydrolase enzyme (expressed in the retinal pigment epithelium) that converts vitamin A from an inactive to an active form, and is responsible for rod and cone functioning.

NEW ORLEANS — Gene augmentation by voretigene neparvovec (Luxturna) improves functional vision in patients with biallelic mutation in the RPE65 gene, a mutation that results in inherited retinal disease, researchers reported here.

Twenty seven of 29 (93%) of patients with Leber congenital amaurosis (LCA) who were treated with the investigational gene therapy had their vision improved to the degree that they could navigate a maze in low to moderate light. They also demonstrated improvement in light sensitivity and peripheral vision, according to Stephen R. Russell, MD, of the University of Iowa in Iowa City, and colleagues.

The improvement was maintained to 3 years, according to updated data from a phase III study presented at the American Academy of Ophthalmology (AAO) meeting.

In October, an FDA advisory committee unanimously recommended approval of the gene treatment for patients with vision loss due to confirmed biallelic RPEmutation-associated retinal dystrophy. The FDA is expected to render a decision no later than January 2018.

“So far, we have followed patients for up to 4 years, and have not seen any significant drop-off,” Russell said at an AAO, press briefing. “We will be observing these patients up to 15 years by FDA protocol.”

RPE65 is an isomerohydrolase enzyme expressed in the retinal pigment epithelium; this enzyme converts vitamin A from an inactive to an active form. The expression of the RPE65 gene is responsible for rod and cone functioning. Autosomal-recessive mutations in the RPE65 gene result in difficulty in navigating unfamiliar environments, night blindness, loss of visual acuity, and a progressive loss of the visual field.

The effect of noretigene neparvovec was studied in a 1-year open-label, randomized, controlled study period, after which patients in the control group could cross over to active treatment. The treatment was delivered bilaterally, 6 to 18 days apart.

The 31 patients, ages 4 to 44 years at the time of treatment, were randomized in a 2:1 ratio to treatment (n=21) or control (n=10).

The primary endpoint was the change in bilateral performance in the multi-luminance mobility test (MLMT), an endpoint designed specifically for LCA, at 1 year. The MLMT measures functional performance through navigation of a mobility course in which participants follow arrows and avoid obstacles. The test was conducted at various light levels, ranging from 1 to 400 lux. The course navigation was captured on video and graded for accuracy and time.

At 1 year, per the mean change in the bilateral MLMT score differed by 1.6 in favor of the active treatment (95% CI 0.72-2.41, P=0.0013). Those who received gene therapy also showed a marked improvement compared with controls in full-field light sensitivity (FST) threshold testing averaged over both eyes (P=0.0004) and MLMT change score for the first injected eye (P=0.0005).

However, the change in visual acuity averaged over both eyes was not significantly different between intervention and control patients (P=0.17).

The mean bilateral MLMT score change at 3 years for 20 patients originally randomized to gene augmentation was 1.8. In nine patients who crossed over, the mean bilateral score change was 2.1 relative to injection baseline after year 1.

Similarly, the mean change from baseline in white light FST was 2.04 at year 3 in 19 participants who received noretigene neparvovec. This same score improved by 2.69 at year 2 in the nine patients who crossed over.

The change in mean visual acuity score was consistent through year 2 for the crossover population and through year 3 in the population originally randomized to noretigene neparvovec. “We have a very small population, so there’s a lot of variability,” Russell stated.

“There were no serious ocular surgery concerns,” he said. “The complications that we saw were largely related to the procedure of placing the subretinal gene therapy as opposed to agent-related reactions.”

Ten patients (17%) had cataracts and three (10%) had intraoperative retinal tears that were treated at the time of gene therapy. Three patients (10%) had retinal deposits.

Irene Maumenee, MD, of the Ocular Genetics Laboratory at the University of Illinois in Chicago, said the results represent the beginning of a treatment wave of genetic eye disease, with further improvements down the road. She cautioned that it may be premature to treat without a full understanding of the variation in disease that occurs with mutation in the same gene.

“Has there ever been any treatment where the dosage was right from the beginning?” she stated. “Probably not. So if this is the first wave of treatment that would be 100% correct, [that ] is … maybe presumptuous. There are so many problems to overcome from the beginning.” Maumenee was not involved in the study.

Russell disclosed a relevant relationship with Spark Therapeutics.

1969-12-31T19:00:00-0500

last updated

Tagged with:

About author

Related Articles